Atherosclerosis in psoriatic disease: Latest evidence and clinical implications

Therapeutic Advances in Musculoskeletal Disease

Volumn 7, Issue 5, 2015, Pages 187-195

  Eder, Lihi ^a   Gladman, Dafna D ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

atherosclerosis; cardiovascular disease; inflammation; psoriatic arthritis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; INTERLEUKIN 1BETA; LEUKOCYTE ANTIGEN; LIPOPROTEIN A; METHOTREXATE; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); MORBIDITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR;

EID: 84942108650     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X15591801     Document Type: Review

References (66)

1. Agewall S. Degroot E. Marcos-Alberca P. Zamorano J. Barrero A. Badano L. et al (2012) Ultrasound and radiology surrogate Eendpoints in pharmacological studies. Atherosclerosis 224: 12–24.
2. Ahlehoff O. Gislason G. Charlot M. Jorgensen C. Lindhardsen J. Olesen J. et al (2011) Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 270: 147–157.
3. Ahlehoff O. Skov L. Gislason G. Gniadecki R. Iversen L. Bryld L. et al (2014) Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol 29: 1128–1134.
4. Bhole V. Choi H. Burns L. Vera Kellet C. Lacaille D. Gladman D. et al (2012) differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 51: 552–556.
5. Boehncke W. Boehncke S. Tobin A. Kirby B. (2011) The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20: 303–307.
6. Chen Y. Chang Y. Shen J. Chen T. Wang C. Chen C. et al (2012) Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study. Arthritis Rheum 64:1879–1887.
7. Chin Y. Yu H. Li W. Ko Y. Chen G. Wu C. et al (2013) Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. J Eur Acad Dermatol Venereol 27: 1262–1268.
8. Choi H. Hernan M. Seeger J. Robins J. Wolfe F. (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359: 1173–1177.
9. Dubreuil M. Rho Y. Man A. Zhu Y. Zhang Y. Love T. et al (2014) Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) 53: 346–352.
10. Eder L. Chandran V. Gladman D. (2013 a) The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 73: 1990–1996.
11. Eder L. Abji F. Rosen C.F. Chandran V. Gladman D.D. (2014 a) HLA markers for disease severity are associated with a higher burden of atherosclerosis in patients with psoriatic disease. Arth Rheum 66(Suppl.): S275.
12. Eder L. Jayakar J. Pollock R. Pellett F. Thavaneswaran A. Chandran V. et al (2013 b) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 72: 1956–1961.
13. Eder L. Thavaneswaran A. Chandran V. Cook R. Gladman D. (2014 b) Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann Rheum Dis doi: 10.1136/annrheumdis-2014-205267. [Epub ahead of print May 14, 2014].
14. Eder L. Thavaneswaran A. Chandran V. Cook R. Gladman D. (2014 c) Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis 74: 813–817.
15. Eder L. Thavaneswaran A. Chandran V. Shen H. Cook R. Gladman D. (2014 d) Predictors for cardiovascular events in patients with psoriatic arthritis – a cohort study. Arth Rheumatol 66(Suppl.): 542.
16. Gelfand J. Weinstein R. Porter S. Neimann A. Berlin J. Margolis D. (2005) Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 141: 1537–1541.
17. Gladman D. Ang M. Su L. Tom B. Schentag C. Farewell V. (2009) Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68: 1131–1135.
18. Gladman D. Antoni C. Mease P. Clegg D. Nash P. (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl. 2): ii14–ii17.
19. Gonzalez-Juanatey C. Llorca J. Miranda-Filloy J. Amigo-Diaz E. Testa A. Garcia-Porrua C. et al (2007) Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57: 287–293.
20. Han C. Robinson D. Jr Hackett M. Paramore L. Fraeman K. Bala M. (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33: 2167–2172.
21. Hansson G. (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685–1695.
22. Hansson G. Klareskog L. (2011) Pulling down the plug on atherosclerosis: cooling down the inflammasome. Nat Med 17: 790–791.
23. Holzer M. Wolf P. Inzinger M. Trieb M. Curcic S. Pasterk L. et al (2014) Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Invest Dermatol 134: 635–642.
24. Hsu S. Papp K. Lebwohl M. Bagel J. Blauvelt A. Duffin K. et al (2012) Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 148: 95–102.
25. Hugh J. van Voorhees A. Nijhawan R. Bagel J. Lebwohl M. Blauvelt A. et al (2014) From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 70: 168–177.
26. Husted J. Thavaneswaran A. Chandran V. Eder L. Rosen C. Cook R. et al (2011) Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 63: 1729–1735.
27. Ibrahim G. Waxman R. Helliwell P. (2009) The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 61: 1373–1378.
28. Jonasson L. Holm J. Skalli O. Bondjers G. Hansson G. (1986) Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6: 131–138.
29. Karbach S. Croxford A. Oelze M. Schuler R. Minwegen D. Wegner J. et al (2014) Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol 34: 2658–2668.
30. Kimhi O. Caspi D. Bornstein N. Maharshak N. Gur A. Arbel Y. et al (2007) Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36: 203–209.
31. Kwon G. Schroeder J. Amar M. Remaley A. Balaban R. (2008) Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation 117: 2919–2927.
32. Li W. Han J. Manson J. Rimm E. Rexrode K. Curhan G. et al (2012) Psoriasis and risk of nonfatal cardiovascular disease in US women: a cohort study. Br J Dermatol 166: 811–818.
33. Lin Y. Dalal D. Churton S. Brennan D. Korman N. Kim E. et al (2014) Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res (Hoboken) 66: 97–103.
34. Love T. Zhu Y. Zhang Y. Wall-Burns L. Ogdie A. Gelfand J. et al (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71: 1273–1277.
35. Ma C. Harskamp C. Armstrong E. Armstrong A. (2013) The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol 168: 486–495.
36. Mehta N. Krishnamoorthy P. Yu Y. Khan O. Raper A. van Voorhees A. et al (2012 a) The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol 67: 796–798.
37. Mehta N. Li R. Krishnamoorthy P. Yu Y. Farver W. Rodrigues A. et al (2012 b) Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 224: 218–221.
38. Miller I. Ellervik C. Yazdanyar S. Jemec G. (2013 a) Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 69: 1014–1024.
39. Miller I. Skaaby T. Ellervik C. Jemec G. (2013 b) Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis. Br J Dermatol 169: 1180–1187.
40. Moore K. Tabas I. (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145: 341–355.
41. Nestle F. Kaplan D. Barker J. (2009) Psoriasis. N Engl J Med 361: 496–509.
42. Ogdie A. Schwartzman S. Eder L. Maharaj A. Zisman D. Raychaudhuri S. et al (2014 a) Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. J Rheumatol 41: 2315–2322.
43. Ogdie A. Yu Y. Haynes K. Love T. Maliha S. Jiang Y. et al (2014 b) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 74: 326–332.
44. Peters M. Symmons D. McCarey D. Dijkmans B. Nicola P. Kvien T. et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69: 325–331.
45. Prodanovich S. Ma F. Taylor J. Pezon C. Fasihi T. Kirsner R. (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52: 262–267.
46. Ramonda R. Puato M. Punzi L. Rattazzi M. Zanon M. Balbi G. et al (2014) Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine 81: 421–425.
47. Ridker P. (2013 a) Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc 124: 174–190.
48. Ridker P. (2013 b) Moving beyond Jupiter: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep 15: 295.
49. Rose S. Dave J. Millo C. Naik H. Siegel E. Mehta N. (2014) Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative. Arthritis Res Ther 16: R161.
50. Ryan C. Leonardi C. Krueger J. Kimball A. Strober B. Gordon K. et al (2011) Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306: 864–871.
51. Samarasekera E. Neilson J. Warren R. Parnham J. Smith C. (2013) Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 133: 2340–2346.
52. Sattar N. Crompton P. Cherry L. Kane D. Lowe G. McInnes I. (2007) Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 56: 831–839.
53. Sharma A. Reddy M. Sharma K. Dogra S. Vijayvergiya R. (2014) Study of endothelial dysfunction in patients of psoriatic arthritis by flow mediated and nitroglycerine mediated dilatation of brachial artery. Int J Rheum Dis doi: 10.1111/1756-185X.12336. [Epub ahead of print April 4, 2014].
54. Shlyankevich J. Mehta N. Krueger J. Strober B. Gudjonsson J. Qureshi A. et al (2014) Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related co-morbidities. Am J Med 127: 1148–1153.
55. Solomon D. Love T. Canning C. Schneeweiss S. (2010) Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 69: 2114–2117.
56. Stanley T. Zanni M. Johnsen S. Rasheed S. Makimura H. Lee H. et al (2011) TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 96: E146–E150.
57. Tabas I. Williams K. Boren J. (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116: 1832–1844.
58. Tam L. Kitas G. Gonzalez-Gay M. (2014) Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology (Oxford) 53: 1108–1119.
59. Tam L. Li E. Shang Q. Tomlinson B. Li M. Leung Y. et al (2011) Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 70: 705–706.
60. Tam L. Shang Q. Li E. Tomlinson B. Chu T. Li M. et al (2008) Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 59: 1322–1331.
61. Weber C. Noels H. (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17: 1410–1422.
62. Westlake S. Colebatch A. Baird J. Kiely P. Quinn M. Choy E. et al (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 49: 295–307.
63. Wilton K. Ernste F. Crowson C. Matteson E. Kremers H. Sánchez-Menéndez M. (2014) Increased cardiovascular risk in patients recently diagnosed with psoriatic arthritis: a population-based, cohort study. Arth Rheumatol 66(Suppl.): 1852.
64. Wu J. Poon K. (2014) Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both. J Drugs Dermatol 13: 932–934.
65. Yilmazer B. Sahin T. Unlu B. Kir H. Cefle A. (2015) Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity. Rheumatol Int 35: 1385–1392.
66. Zhu T. Li E. Tam L. (2012) Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol 2012: 714321.